Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature

Atienza, Jonessa; Dasanu, Constantin A

doi:10.1185/03007995.2012.746218

Cited by 54 publications

(69 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Europe, the 5-year survival rate varies considerably according to anatomic site, 63.1% for cancer of the larynx, 48.5% for oral cavity, 39.8% for oropharynx and 25.5% for hypopharynx cancer [21]. About 40-60% of HNC patients develop recurrences, and around 20% of HNCs develop second primary cancer (SPC), both being associated with poorer survival [22]. Despite various therapeutic interventions, including surgery, radiotherapy, and chemotherapy, the 5-year survival rate for this disease has improved only marginally during the past two decades.…”

Section: Introductionmentioning

confidence: 99%

Clinical features and prognostic factors in patients with head and neck cancer: Results from a multicentric study

Leoncini

Vuković

Cadoni

et al. 2015

Cancer Epidemiology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Clinical features and prognostic factors in patients with head and neck cancer: Results from a multicentric study

Leoncini

Vuković

Cadoni

et al. 2015

Cancer Epidemiology

View full text Add to dashboard Cite

“…The incidence of a synchronous lung tumor in these cases is 1%, whereas the incidence of a metachronous tumor increases to 10% in patients who have survived ≥3 years (7,10). When the location of primary malignancies was analyzed in the present study, the second most frequent group was respiratory system malignancies with ten cases (22.2%); laryngeal cancer and lung cancer were included in this group.…”

Section: Discussionmentioning

confidence: 99%

Malignite tanılı opere edilmiş ikinci primer akciğer kanserli hastaların uzun dönem sağkalımını etkileyen faktörlerin analizi

Ergönül¹,

Özdil²,

Akçam³

et al. 2015

Ege Tıp Dergisi

View full text Add to dashboard Cite

Aim: Multiple cancer rates increase with an average increased lifespan. Therefore, many malignant patients are at high risk for a second primary malignancy. This study aims to evaluate lung cancer patients with a previous malignancy. Materials and Methods:Forty-five patients who underwent resection for a second primary lung cancer in our department between January 2007 and June 2013 were reviewed retrospectively. Results:The patients included 37 (82.2%) males and eight (17.8%) females. When the patients were evaluated for the first primary malignancy, the distribution of the malignancies according to the systems was 14 (31.1%) urogenital malignancies, ten (22.2%) respiratory, six (13.3%) hematological, six (13.3%) endocrine, five (11.1%) malignancies, and four (8.9%) integumentary malignancies. The comparison of the site of primary malignancy and survival data showed that the rates of long-term survival were shorter in patients with gastrointestinal system malignancies and the difference was statistically significant (p=0.028). The long-term survival of patients who received chemotherapy after the resection of the first primary lung cancer was significantly shorter (p=0.016). Conclusion:The follow-up of patients should be done more carefully by the consideration of the positive effects of early diagnosis on cancer prognosis and keeping in mind the risk of primary lung cancer development in a patient with other system malignancy. We especially recommend caution in administering chemotherapy to patients with double primary tumors after a lung cancer operation. Keywords

show abstract

“…Current data wasn't sufficient to evaluate second primary statistically, however it is not easy to obtain sufficient sample of this rare tumor, A systematic review by Atienza, Jonessa Ann S et al [23] reported high incidence of second primaries in head and neck sites, according to them environmental, genetic and immunological factors could explain such association.…”

Section: Discussionmentioning

confidence: 99%

Oral Hybrid Verrucous Carcinoma: A Clinical Study

Gokavarapu

Tantravahi

Gundimeda

et al. 2014

Indian J Surg Oncol

View full text Add to dashboard Cite

Hybrid Verrucous Carcinoma is an uncommon tumour wherein Verrucous Carcinoma (VC) is coexisting with conventional Squamous Cell Carcinoma (SCC) within same maternal field. The heterogeneous nature, infrequency of occurrence and the difficulties associated with diagnosis and management of this tumor is discussed through a retrospective study. Patients of primary hybrid VC treated from Jan 2010 to May 2013 at a tertiary institute were analyzed on multivariate cox regression model. During the above mentioned period; 37 patients of hybrid VC were reported; 18(48.6 %) were male and 19(51.3 %) were female. Age ranged between 33 years to 78 years. Median follow up period was 32 months. T stage status and Stage grouping was not statistically significant for mortality (p value: 0.338). In the multivariate cox-regression model, the presence of second primary oral cancer was significantly associated with mortality, adjusted HR; 23.10 (95 % CI: 1.73, 307.65) (p=0.017). Tumour staging is often unreliable in predicting prognosis of hybrid VC, occurrence of second primary oral cancer and recurrence appears to be significant factors effecting prognosis.

show abstract

Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature

Cited by 54 publications

References 57 publications

Clinical features and prognostic factors in patients with head and neck cancer: Results from a multicentric study

Clinical features and prognostic factors in patients with head and neck cancer: Results from a multicentric study

Malignite tanılı opere edilmiş ikinci primer akciğer kanserli hastaların uzun dönem sağkalımını etkileyen faktörlerin analizi

Oral Hybrid Verrucous Carcinoma: A Clinical Study

Contact Info

Product

Resources

About